Orca Investment Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,784 shares of the biopharmaceutical company’s stock after selling 1,232 shares during the quarter. Orca Investment Management LLC’s holdings in Pfizer were worth $1,004,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Schaper Benz & Wise Investment Counsel Inc. WI boosted its holdings in Pfizer by 0.5% during the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 228,630 shares of the biopharmaceutical company’s stock valued at $10,076,000 after acquiring an additional 1,170 shares during the period. Clean Yield Group boosted its holdings in Pfizer by 1.9% during the third quarter. Clean Yield Group now owns 64,375 shares of the biopharmaceutical company’s stock valued at $2,837,000 after acquiring an additional 1,170 shares during the period. Adams Asset Advisors LLC boosted its holdings in Pfizer by 0.8% during the third quarter. Adams Asset Advisors LLC now owns 157,717 shares of the biopharmaceutical company’s stock valued at $6,951,000 after acquiring an additional 1,182 shares during the period. Exeter Financial LLC boosted its holdings in Pfizer by 3.9% during the second quarter. Exeter Financial LLC now owns 31,817 shares of the biopharmaceutical company’s stock valued at $1,154,000 after acquiring an additional 1,195 shares during the period. Finally, Smart Portfolios LLC boosted its holdings in Pfizer by 43.9% during the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 1,200 shares during the period. 69.26% of the stock is currently owned by hedge funds and other institutional investors.
PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price target on shares of Pfizer in a report on Wednesday, October 17th. Barclays set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Friday, October 19th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, October 30th. Credit Suisse Group set a $40.00 target price on shares of Pfizer and gave the company a “hold” rating in a research note on Sunday, October 14th. Finally, Wolfe Research started coverage on shares of Pfizer in a research note on Tuesday, October 23rd. They issued a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $43.41.
NYSE PFE opened at $42.88 on Monday. The stock has a market capitalization of $258.00 billion, a P/E ratio of 16.18, a P/E/G ratio of 2.11 and a beta of 0.87. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $46.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 3 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, February 1st will be paid a dividend of $0.36 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.34. The ex-dividend date of this dividend is Thursday, January 31st. This represents a $1.44 dividend on an annualized basis and a yield of 3.36%. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
Pfizer declared that its Board of Directors has approved a share repurchase program on Friday, December 14th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to buy up to 3.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: “Orca Investment Management LLC Has $1 Million Holdings in Pfizer Inc. (PFE)” was reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/01/14/orca-investment-management-llc-has-1-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: Earnings Per Share (EPS) Explained
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.